Marcia S. Brose, MD, PhD, FASCO

Marcia S. Brose, MD, PhD, FASCO, discusses potential next steps for approaching and treating patients with advanced or metastatic RET-mutant thyroid cancer.

Marcia S. Brose, MD, PhD, FASCO, discusses her hopes for the future of selpercatinib in treating advanced or metastatic RET-mutant thyroid cancer.

Marcia S. Brose, MD, PhD, discusses treatment sequencing practices and offers advice for community oncologists treating patients with RAI-R-DTC.

Focusing on lenvatinib, an expert on RAI-R-DTC discusses data on real-world treatment patterns and clinical outcomes and gives an overview of papers on age and dose.

Marcia S. Brose, MD, PhD, discusses her experience with lenvatinib as a treatment for patients with RAI-R-DTC.

An expert on radioiodine-refractory differentiated thyroid cancer outlines factors to consider when selecting appropriate treatments for patients.

Clinical insights on the standard-of-care treatment of patients with advanced RAI-R-DTC, the NCCN guideline recommendations, and challenges encountered in treatment.

Marcia S. Brose, MD, PhD, discusses the frontline treatment landscape for patients with advanced RAI-R-DTC, focusing on sorafenib and the DECISION trial as well as lenvatinib and the SELECT trial.

A medical oncologist gives an overview of radioiodine-refractory differentiated thyroid cancer, with a focus on diagnosis and patient presentation.

Marcia S. Brose, MD, PhD, presents the case of a 43-year-old man with radioiodine-refractory differentiated thyroid cancer (RAI-R-DTC) and offers her initial impressions.

Marcia S. Brose, MD, PhD, FASCO, discusses the landscape of thyroid cancer by explaining the complexities and promising advancements seen in the space.

Marcia S. Brose, MD, PhD, FASCO, discusses trials LIBRETTO program leading up to LIBRETTO-531.

Marcia S. Brose, MD, PhD, FASCO, discusses NTRK gene fusions and identifying patients with thyroid cancer.

In the second interview of the series, Marcia Brose, MD, PhD, reviews currently available therapies for NTRK fusion-positive thyroid cancer and highlights clinical factors affecting treatment decision-making.

In the second video of the series, Marcia Brose, MD, PhD, from the Sidney Kimmel Cancer Center – Jefferson Health shares key insights into factors affecting treatment decisions for patients with TRK fusion-positive cancers including the consideration of comorbidities and adverse event profiles.

Marcia Brose, MD, PhD, discusses a global, non-interventional study that assessed the use of sorafenib as treatment of patients with asymptomatic radioiodine-refractory differentiated thyroid cancer.

Marcia Brose, MD, PhD, discusses how the thyroid cancer treatment landscape will be impacted by the positive findings regarding larotrectinib in the presence of a TRK fusion.

Marcia Brose, MD, PhD, discusses the safety findings from an analysis of larotrectinib as treatment of patients with metastatic solid tumors.

Marcia Brose, MD, PhD, discusses the importance of genomic testing in patients with thyroid cancer.

Marcia Brose, MD, PhD, discusses the treatment options for patients with thyroid cancer and NTRK fusions.

Marcia S. Brose, MD, PhD, discusses the SELECT trial, which looks at lenvatinib for patients with 131I-refractory differentiated thyroid cancer.

Marcia S. Brose, MD, PhD, associate professor of Otorhinolaryngology: Head and Neck Surgery at the Hospital of the University of Pennsylvania, discusses the effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in the SELECT trial.

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center at the University of Pennsylvania, discusses next-generation sequencing in thyroid cancer.

Marcia S. Brose, MD, PhD, discusses using both sorafenib and lenvatinib as treatment options for thyroid cancer.

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, discusses the tolerability and safety of sorafenib as seen in patients with thyroid cancer.

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, discusses the updated overall survival analysis of the phase III DECISION trial, which looked at sorafenib for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC).

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, University of Pennsylvania, discusses research into vandetanib for the treatment of patients with differentiated thyroid cancer.

Marcia S. Brose, MD, PhD, describes the DECISION trial, which analyzed the efficacy of sorafenib in differentiated thyroid cancer.

Marcia S. Brose, MD, PhD, Abramson Cancer Center, University of Pennsylvania, discusses BRAF mutations in thyroid cancer.a

Marcia Brose, MD, PhD, from the University of Pennsylvania, on repurposing drugs to treat thyroid cancer.